Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

KALAMAZOO, Mich. — Those who are recovering from addiction now have a new lifeline in Kalamazoo. Reach Sober Living has just ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

The relatively new and less detectable product’s increasing prevalence among youth underscores an urgent need for informed ...

Kennedy is Trump’s pick for health secretary, but he has a history of spreading misinformation about a range of issues.